^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Hemasalus™

    Company:
    Geneseeq
    Type:
    CE Marked
    Related tests:

    Details

    Evidence
    News
    Hemasalus™ analyses mutations and selected translocations of 475 key genes in hematologic malignancies by targeted DNA-sequencing (Hemasalus™ D), or in combination with whole transcriptome mRNA-sequencing (Hemasalus™ DR) to detect a broader range of gene translocations and expression changes.
    Cancer:
    Hematological Malignancies, Leukemia, Multiple Myeloma
    Method:
    Comprehensive Genomic Profiling
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    08/22/23
    Heme
    -
    CE